Brief: Editas Medicine Announces New Safety And Efficacy Data From The Edithal Trial Of Reni-Cel
14/06/2024 08:01
June 14 (Reuters) - Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE ANNOUNCES NEW SAFETY AND EFFICACY DATA
FROM THE
EDITHAL TRIAL OF RENI-CEL IN 7 PATIENTS WITH
TRANSFUSION-DEPENDENT BETA THALASSEMIA, PRESENTED AT THE
EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL CONGRESS
* ALL PATIENTS TREATED IN EDITHAL TRIAL MAINTAINED
HEMOGLOBIN
LEVELS ABOVE TRANSFUSION THRESHOLD AND ARE TRANSFUSION-FREE
Source text for Eikon: ID:nGNX1LH5kM
Further company coverage: EDIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering